HC Wainwright Issues Pessimistic Forecast for BHST Earnings

BioHarvest Sciences Inc. (NASDAQ:BHST) – Equities researchers at HC Wainwright decreased their Q3 2025 earnings per share estimates for shares of BioHarvest Sciences in a report released on Tuesday, August 12th. HC Wainwright analyst A. Dayal now expects that the company will earn ($0.10) per share for the quarter, down from their previous forecast of ($0.06). The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.53) EPS, FY2026 earnings at $0.04 EPS, FY2027 earnings at $0.29 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $1.14 EPS.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.04). BioHarvest Sciences had a negative return on equity of 11,357.84% and a negative net margin of 39.95%. The firm had revenue of $8.52 million for the quarter, compared to analysts’ expectations of $8.53 million.

Separately, Craig Hallum assumed coverage on BioHarvest Sciences in a research report on Monday, May 5th. They set a “buy” rating and a $15.00 price target for the company.

BioHarvest Sciences Stock Performance

Shares of BHST opened at $9.32 on Thursday. BioHarvest Sciences has a one year low of $4.66 and a one year high of $9.90. The stock has a market capitalization of $153.03 million, a price-to-earnings ratio of -13.31 and a beta of 0.68. The stock has a 50 day moving average price of $7.41 and a 200 day moving average price of $6.46.

Institutional Trading of BioHarvest Sciences

Several large investors have recently made changes to their positions in the company. True North Advisors LLC grew its holdings in BioHarvest Sciences by 7.6% in the 1st quarter. True North Advisors LLC now owns 44,391 shares of the company’s stock valued at $275,000 after buying an additional 3,120 shares in the last quarter. Magnus Financial Group LLC grew its holdings in BioHarvest Sciences by 105.0% in the 1st quarter. Magnus Financial Group LLC now owns 71,733 shares of the company’s stock valued at $444,000 after buying an additional 36,733 shares in the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in BioHarvest Sciences in the 4th quarter valued at $69,000.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.